Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate A — John Didsbury (T3D THERAPEU
T3D-959 is a novel (non-amyloid/non-tau-directed) new chemical entity aimed at improving dysfunctional brain glucose energy and lipid metabolism in Alzheimer’s disease (AD). T3D-959 is an orally deliv
| Project title | Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate A |
|---|---|
| Project number | 3R01AG061122-03S1 |
| PI name | John Didsbury |
| Institution | T3D THERAPEUTICS, INC. |
| Funding mechanism | R01 |
| Agency | NIA |
| Award amount | $5.53M |
| Fiscal year | 2022 |
| Project start | 2019-05-01T00:00:00 |
| Project end | 2023-02-28T00:00:00 |
| Abstract | T3D-959 is a novel (non-amyloid/non-tau-directed) new chemical entity aimed at improving dysfunctional brain glucose energy and lipid metabolism in Alzheimer’s disease (AD). T3D-959 is an orally deliv |
| Key terms | <A β-42><A β42><A-beta 42><A-beta42><AD dementia><Abeta-42><Abeta42><Administrative Supplement><Agon |
$799/mo
Try GrantRadar →